In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods and more. The goal: To allow regulatory professionals to better anticipate and prepare for upcoming events and catalysts.
What we expect to be talking about in April:
Mifepristone (again): In March, we expected that we would be spending most of the month talking about mifepristone due to a court case in Texas, which was expected to conclude with an order fully or partially revoking the approach of the abortion drug mifepristone.
Fill out the form to read the full article.
